Suven declares dose administration of 1st patient in Phase 2A clinical trial of SUVN G-3031
Suven Life Sciences has declared dose administration of the first patient in a Phase 2A clinical trial of SUVN G-3031, a Histamine H3 receptor inverse agonist in a Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients with Narcolepsy … Read more